RxSight Inc (NAS:RXST)
$ 4.95 -0.14 (-2.85%) Market Cap: 204.91 Mil Enterprise Value: -2.14 Mil PE Ratio: 0 PB Ratio: 0.77 GF Score: 68/100

Preliminary Q2 2026 Rxsight Inc Earnings Call Transcript

Jul 07, 2026 / 12:00PM GMT
Release Date Price: $5.62 (+0.36%)
Operator

Hello, and thank you for standing by. My name is John, and I will be your conference operator today. At this time, I would like to welcome everyone to the RxSight preliminary second-quarter financial results and product pipeline updates following Collaboration Agreement. (Operator Instructions)

I would now like to turn the conference over to Oliver Moravcevic, VP of Investor Relations. Please go ahead.

Oliver Moravcevic
Rxsight Inc - Vice President, Investor Relations

Thank you, operator. With me on the call this morning is RxSight President and Chief Executive Officer, Dr. Ron Kurtz; and Chief Financial Officer, Mark Wilterding. Yesterday, RxSight released a pair of press releases, one reporting a new Collaboration Agreement with Alcon and the second reporting preliminary revenue results for the three months ending June 30, 2026, updated product pipeline and revised full-year guidance. Copies of both press releases and corresponding 8-Ks are available on the company's website.

Before we begin, I would like to inform you that comments and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot